Insider Selling: ResMed (NYSE:RMD) CEO Sells $1,110,198.04 in Stock

Posted by George Bondi on Sep 13th, 2026

ResMed Inc. (NYSE:RMD – Get Free Report) CEO Michael Farrell sold 4,991 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $222.44, for a total value of $1,110,198.04. Following the transaction, the chief executive officer directly owned 466,256 shares in the company, valued at $103,713,984.64. This represents a 1.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Trading Down 0.6%

Shares of RMD opened at $218.28 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.42 and a current ratio of 3.10. The firm has a market cap of $31.49 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 1.38 and a beta of 0.77. ResMed Inc. has a fifty-two week low of $180.26 and a fifty-two week high of $284.87. The business has a 50-day moving average of $217.39 and a 200 day moving average of $217.00.

ResMed (NYSE:RMD – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share for the quarter, topping the consensus estimate of $2.89 by $0.06. ResMed had a net margin of 26.94% and a return on equity of 25.58%. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter last year, the company earned $2.55 earnings per share. The company’s revenue was up 8.6% on a year-over-year basis. As a group, research analysts forecast that ResMed Inc. will post 12.02 EPS for the current year.

ResMed Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 24th. Shareholders of record on Thursday, August 20th will be issued a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Thursday, August 20th. This is a boost from ResMed’s previous quarterly dividend of $0.60. ResMed’s payout ratio is presently 25.31%.

Institutional Investors Weigh In On ResMed

Hedge funds have recently bought and sold shares of the stock. Jones Financial Companies Lllp increased its holdings in shares of ResMed by 52.6% in the 1st quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider’s stock worth $645,000 after buying an additional 994 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of ResMed during the 2nd quarter worth $389,000. Brown Advisory Inc. lifted its holdings in shares of ResMed by 17.8% during the 2nd quarter. Brown Advisory Inc. now owns 1,586 shares of the medical equipment provider’s stock worth $409,000 after acquiring an additional 240 shares during the last quarter. Cresset Asset Management LLC bought a new stake in shares of ResMed during the 2nd quarter worth $206,000. Finally, Alliancebernstein L.P. grew its position in ResMed by 24.2% in the second quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider’s stock worth $73,808,000 after acquiring an additional 55,790 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

RMD has been the subject of several recent analyst reports. KeyCorp boosted their price objective on shares of ResMed from $255.00 to $267.00 and gave the company an “overweight” rating in a research note on Monday, August 31st. Weiss Ratings upgraded shares of ResMed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Jefferies Financial Group cut their price target on shares of ResMed from $240.00 to $225.00 and set a “hold” rating for the company in a report on Friday, July 10th. The Goldman Sachs Group restated a “buy” rating on shares of ResMed in a research report on Wednesday, July 1st. Finally, Robert W. Baird set a $213.00 price target on shares of ResMed in a report on Friday, August 7th. Six research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, ResMed currently has an average rating of “Hold” and an average target price of $240.31.

View Our Latest Stock Analysis on ResMed

About ResMed

(Get Free Report)

ResMed Inc is a medical equipment and software company that develops products and services for the diagnosis and treatment of sleep-disordered breathing and other respiratory conditions. Its offerings include continuous positive airway pressure (CPAP) and other positive airway pressure devices, masks, ventilation systems, oxygen-related solutions, and connected health technologies.

The company also provides cloud-based software and digital health platforms that help clinicians, home medical equipment providers, and patients monitor therapy, manage equipment, and support adherence to treatment.